Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …

Monoclonal antibodies (mAbs) offer a treatment option for individuals with severe COVID-19
and are especially important in high-risk individuals where vaccination is not an option …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a recently emerged
pathogenic human coronavirus that belongs to the sarbecovirus lineage of the genus …

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant of
concern evades antibody-mediated immunity that comes from vaccination or infection with …

The emergence of the highly transmissible B. 1.1. 529 Omicron variant of severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) is concerning for antibody …

The unprecedented public health and economic impact of the COVID-19 pandemic caused
by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been …

Although most mutations in the severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) genome are expected to be either deleterious and swiftly purged or relatively …

Two and a half years into the COVID-19 pandemic, we have gained many insights into the
human antibody response to the causative SARS-CoV-2 virus. In this Review, we …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the global
COVID-19 pandemic. Rapidly spreading SARS-CoV-2 variants may jeopardize newly …

Transmission of SARS-CoV-2 is uncontrolled in many parts of the world; control is
compounded in some areas by the higher transmission potential of the B. 1.1. 7 variant …